Key result
Clofibrate use is linked to a ~29% triglyceride reduction in type IV and mixed hyperlipoproteinemia.
Why the study?
The effect of clofibrate on plasma lipids and lipoprotein patterns in patients with mild type IV and mixed hyperlipoproteinaemia was not well characterized.
Does clofibrate improve plasma lipids and lipoprotein patterns in patients with type IV and mixed hyperlipoproteinaemia?
Comparison
Before and after clofibrate treatment
Design
Observational study
Authors
Loading...
May support triglyceride management in type IV hyperlipoproteinaemia; leaves open outcome effects in randomized trials.
Observational (n=40)
Does clofibrate improve plasma lipids and lipoprotein patterns in patients with type IV and mixed hyperlipoproteinaemia?
Clofibrate effectively reduces total triglycerides by approximately 29% in patients with type IV and mixed hyperlipoproteinaemia, normalizing the serum lipid pattern in about one third of patients.
Miettinen et al. (1972) conducted an observational in Type IV and mixed hyperlipoproteinaemia (n=40). Clofibrate was evaluated on Plasma lipids, immunological β‐lipoprotein and electrophoretic lipoprotein pattern. Clofibrate decreased total triglycerides by 29% in patients with type IV and mixed hyperlipoproteinaemia, normalizing the serum lipid pattern in about one third of hyperglyceridaemic patients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: